15 articles
A survey says 100% of respondents plan to use agentic AI within two years, yet AI reaches 30% or less of company data at 'laggard' firms. SEC-checked Nvidia figures show where spending lands, and a source with a poor reliability record is flagged.
SEC-filed figures show Micron nearly doubled its annual capital spending in FY2025 and held almost $25 billion in cash by Q3 2026. Around that checked core, analyst calls on power, data-center and memory names look strong. Quantum and consumer stocks look stretched or weak. We flag which sources held up.
Enterprise AI agents are reaching production at banks, insurers and health administrators. The research on data readiness is weaker: the one source that quantifies it failed every check we ran on it. The verified SEC figures show where spending has clearly landed, which is Nvidia's cost base.
Vertical AI startups are pitching to replace labor budgets, and Nvidia's verified filings show what building the underlying compute costs. But a Google Cloud-based finding in Via News's narrative says firms give agents only 45% of their data. The source that reported the 100%-adoption plan has a weak accuracy record.
Google quietly loosened its AI watermarking rules and OpenAI lost another senior executive in the same week — while claimed AI infrastructure spending kept accelerating and enterprise ROI claims from AI vendors ranged from well-documented to speculative. Via News traces the money behind the governance headlines.
Vicor trades near 24x trailing revenue on $471.7M in sales even as semiconductor equities sell off; Solitron's backlog grew 28% while Amkor guided below consensus. Via News traces the earnings, M&A and capital data behind the divergence — including a leveraged ETF that swung from a 196% one-year gain to a 17% one-day collapse.
Late-July's chip selloff hit a sector still signing nine-figure supply deals: Vicor posted $471.7M TTM revenue against an $11.3B market cap, Washington moved toward a $300M equity-linked stake in GlobalFoundries, and Amkor guided below consensus — a market repricing execution risk, not the AI capex thesis.
Survey data cited by MIT Technology Review claims 100% of enterprises plan agentic AI within two years, but its own reliability record is weak. What is verifiable: Manulife's five-year Microsoft deal, Box's new agent controls, and venture capital pricing narrow, auditable finance and healthcare workflows as the safer bet.
Brad Lightcap, OpenAI's special projects lead and the company's former chief operating officer, has announced his departure from the company.
Microsoft has captured 900 million monthly AI users and 90% of Fortune 500 companies with its Copilot platform, but persistent capacity constraints through fiscal year-end reveal infrastructure struggles to meet surging enterprise demand. The gap has triggered a industry-wide scramble as legacy software vendors and non-tech firms pivot to AI capabilities while regional players pursue alternative strategies like quantum computing research.
A wave of experimental immunotherapy platforms is approaching commercialization as AstraZeneca, Syndax, Eledon, and OS Therapies advance novel treatments through late-stage trials and regulatory reviews. The companies are targeting cancers and conditions that have historically resisted treatment, with multiple therapies expected to reach patients in 2026.
A concentrated wave of positive clinical trial results has emerged across four therapeutic areas in early 2026, with multiple drug candidates meeting primary endpoints simultaneously. The convergence of success in multiple sclerosis, lupus, heart rhythm disorders, and blood cancer treatments reflects a maturing cycle of pharmaceutical development that could reshape treatment options within two years.
Pharmaceutical giants are aggressively consolidating oncology assets through strategic acquisitions and breakthrough regulatory approvals, signaling a fundamental shift in how the industry approaches cancer treatment development. Johnson & Johnson's recent acquisitions of Shockwave Medical and Halda Therapeutics, combined with FDA approvals for advanced combination therapies, reflect a broader industry trend toward concentrating next-generation cancer platforms within established pharmaceutical
NVIDIA is positioning itself as the dominant infrastructure provider for AI-driven pharmaceutical research through its BioNeMo platform, securing partnerships with major players including Thermo Fisher and Eli Lilly. The move represents a strategic expansion beyond traditional computing applications into the life sciences sector, where AI-native biotech firms are increasingly relying on specialized hardware for drug discovery.
Broadcom has secured more than $21 billion in custom AI accelerator orders from hyperscale cloud providers, marking a strategic transformation from its traditional semiconductor and enterprise software roots into a essential supplier for the artificial intelligence infrastructure race. The orders, including commitments from Anthropic and at least four other major customers, position the company at the center of the industry's massive datacenter expansion.